Immunic appoints Michael Bonney as Board Chair
Immunic appointed biopharmaceutical veteran Michael Bonney as Chair of the Board, effective May 16, 2026, replacing interim chair Simona Skerjanec who remains as director. Bonney brings 30+ years of industry experience including leadership at Biogen during Avonex's MS launch and prior CEO role at Cubist Pharmaceuticals, which was acquired by Merck for $9.5 billion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day